Induction Camrelizumab and Modified TPF (Nab‐Paclitaxel, Cisplatin, and S‐1) in Locoregionally Advanced Nasopharyngeal Carcinoma

ABSTRACT Induction chemo‐immunotherapy has emerged as a potential treatment option for locoregionally advanced nasopharyngeal carcinoma (LANPC). This study aimed to evaluate the efficacy and safety of camrelizumab combined with modified TPF (nab‐paclitaxel, cisplatin, and S‐1) as induction chemo‐immunotherapy in LANPC. Patients with stage T1‐4N2‐3M0 NPC who received induction chemo‐immunotherapy were enrolled from July 2023 to May 2024. They underwent three cycles of chemo‐immunotherapy, including camrelizumab 200 mg on day 1, nab‐paclitaxel 260 mg/m 2 on day 1, cisplatin 25 mg/m 2 on days 1–3, and oral S‐1 40–60 mg twice daily from days 1 to 14, every 21 days. The primary endpoint was the complete response (CR) rate, while secondary endpoints included the safety and objective response rate (ORR). A total of 30 patients were enrolled, with 29 (96.7%) completing three cycles of induction chemo‐immunotherapy. The CR rate was 41.4% (12/29), achieving the predefined endpoint. The CR rate for the primary nasopharyngeal tumor and cervical lymph nodes was both 65.5% (19/29). Seventeen patients achieved a partial response (PR), resulting in an ORR of 100%. Grade 3 or 4 chemotherapy‐related adverse events occurred in 26.6% of patients. Immune‐related adverse events of any grade were reported in 20 (66.7%) patients, including reactive cutaneous capillary endothelial proliferation in 10 patients (40.0%), all of which were Grade 1 or 2. One patient (3.5%) experienced a Grade 3 rash. No treatment‐related deaths occurred. Our study suggests that induction chemo‐immunotherapy of camrelizumab plus modified TPF demonstrated an excellent CR rate and an acceptable safety profile in patients with LANPC. Trial Registration: ChiCTR240008603